Expanding Therapeutic Options in De Novo Metastatic Hormone-Sensitive Prostate Cancer: Overcoming Resistance to Traditional Therapies

Expanding Therapeutic Options in De Novo Metastatic Hormone-Sensitive Prostate Cancer

Overcoming Resistance to Traditional Therapies CME/CNE/CPE

Friday, May 3, 2024 | 6:00 pm - 7:30 pm CT

Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP